Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Gains from Investment Securities: 2019-2022

Historic Gains from Investment Securities for C4 Therapeutics (CCCC) over the last 1 years, with Mar 2022 value amounting to $44.1 million.

  • C4 Therapeutics' Gains from Investment Securities rose 640.26% to $44.1 million in Q1 2022 from the same period last year, while for Mar 2022 it was $69.9 million, marking a year-over-year increase of 1073.78%. This contributed to the annual value of $44.1 million for FY2022, which is 118.90% up from last year.
  • Per C4 Therapeutics' latest filing, its Gains from Investment Securities stood at $44.1 million for Q1 2022, which was up 118.90% from $20.1 million recorded in Q4 2021.
  • C4 Therapeutics' 5-year Gains from Investment Securities high stood at $44.1 million for Q1 2022, and its period low was $2.3 million during Q4 2019.
  • Its 3-year average for Gains from Investment Securities is $13.7 million, with a median of $6.1 million in 2021.
  • Data for C4 Therapeutics' Gains from Investment Securities shows a peak YoY spiked of 694.12% (in 2021) over the last 5 years.
  • Quarterly analysis of 4 years shows C4 Therapeutics' Gains from Investment Securities stood at $2.3 million in 2019, then rose by 9.70% to $2.5 million in 2020, then spiked by 694.12% to $20.1 million in 2021, then soared by 640.26% to $44.1 million in 2022.
  • Its Gains from Investment Securities stands at $44.1 million for Q1 2022, versus $20.1 million for Q4 2021 and $6.2 million for Q2 2021.